PDF(Pubmed)
Abstract：
UNASSIGNED: Contrast-induced nephropathy (CIN) is a common post-procedural complication of percutaneous coronary intervention for acute myocardial infarction (AMI). Anisodamine hydrobromide is an alkaloid that has demonstrated efficacy in improving microcirculation. This meta-analysis aims to evaluate the reno-protective effects of Anisodamine in patients undergoing percutaneous coronary intervention (PCI) for AMI.
UNASSIGNED: PubMed, Embase, Cochrane Library, Scopus, and clinicaltrials.gov were searched from inception to January 2024 for randomized controlled trials (RCTs) comparing the efficacy of Anisodamine in preventing the development of CIN. Outcomes of interest included the incidence of CIN, serum creatinine levels, and estimated glomerular filtration rate (eGFR). A random-effects model was used for pooling standard mean differences (SMDs) and odds ratios (ORs) with a 95% CI. Statistical significance was considered at a P less than 0.05.
UNASSIGNED: Three RCTs involving 563 patients were included. Anisodamine was associated with a reduction in the incidence of CIN [OR: 0.44; 95% CI: 0.28, 0.69; P=0.0003], a reduction in serum creatinine levels at 48 [SMD: -6.78; 95% CI: -10.54,-3.02; P=0.0004] and 72 h [SMD: -6.74; 95% CI: -13.33,-0.15; P=0.03], and a higher eGFR at 24 [SMD: 5.77; 95% CI: 0.39, 11.14; P=0.03], and 48 h [SMD: 4.70; 95% CI: 2.03,7.38; P=0.0006]. The levels of serum creatinine at 24 h and eGFR value at 72 h were comparable between both groups.
UNASSIGNED: Anisodamine has demonstrated clinical efficacy in ameliorating the development of CIN post-PCI in AMI patients. Large, multi-centric RCTs are warranted to evaluate the robustness of these findings.
UNASSIGNED: PubMed, Embase, Cochrane Library, Scopus, and clinicaltrials.gov were searched from inception to January 2024 for randomized controlled trials (RCTs) comparing the efficacy of Anisodamine in preventing the development of CIN. Outcomes of interest included the incidence of CIN, serum creatinine levels, and estimated glomerular filtration rate (eGFR). A random-effects model was used for pooling standard mean differences (SMDs) and odds ratios (ORs) with a 95% CI. Statistical significance was considered at a P less than 0.05.
UNASSIGNED: Three RCTs involving 563 patients were included. Anisodamine was associated with a reduction in the incidence of CIN [OR: 0.44; 95% CI: 0.28, 0.69; P=0.0003], a reduction in serum creatinine levels at 48 [SMD: -6.78; 95% CI: -10.54,-3.02; P=0.0004] and 72 h [SMD: -6.74; 95% CI: -13.33,-0.15; P=0.03], and a higher eGFR at 24 [SMD: 5.77; 95% CI: 0.39, 11.14; P=0.03], and 48 h [SMD: 4.70; 95% CI: 2.03,7.38; P=0.0006]. The levels of serum creatinine at 24 h and eGFR value at 72 h were comparable between both groups.
UNASSIGNED: Anisodamine has demonstrated clinical efficacy in ameliorating the development of CIN post-PCI in AMI patients. Large, multi-centric RCTs are warranted to evaluate the robustness of these findings.
摘要：
■造影剂肾病（CIN）是急性心肌梗死（AMI）经皮冠状动脉介入治疗的常见术后并发症。氢溴酸山莨菪碱是一种生物碱，已证明在改善微循环方面具有功效。这项荟萃分析旨在评估山莨菪碱对AMI经皮冠状动脉介入治疗（PCI）患者的肾脏保护作用。
■PubMed,Embase,科克伦图书馆,Scopus,和临床试验从开始到2024年1月进行了随机对照试验（RCT）比较山莨菪碱预防CIN的疗效。感兴趣的结果包括CIN的发生率，血清肌酐水平，和估计的肾小球滤过率(eGFR)。随机效应模型用于汇集标准平均差（SMD）和比值比（OR），CI为95％。在P小于0.05时认为有统计学意义。
■纳入三个RCT，涉及563例患者。山莨菪碱与CIN发生率降低相关[OR：0.44;95%CI：0.28,0.69;P=0.0003],在48[SMD：-6.78;95％CI：-10.54，-3.02;P=0.0004]和72h[SMD：-6.74;95％CI：-13.33，-0.15;P=0.03]时，血清肌酐水平降低，24时eGFR较高[SMD：5.77；95%CI：0.39，11.14；P=0.03]，和48h[SMD：4.70；95%CI：2.03,7.38；P=0.0006]。两组24h时的血清肌酐水平和72h时的eGFR值具有可比性。
■山莨菪碱在改善AMI患者PCI后CIN的发展方面具有临床疗效。大,多中心随机对照试验是必要的,以评估这些结果的稳健性.
■PubMed,Embase,科克伦图书馆,Scopus,和临床试验从开始到2024年1月进行了随机对照试验（RCT）比较山莨菪碱预防CIN的疗效。感兴趣的结果包括CIN的发生率，血清肌酐水平，和估计的肾小球滤过率(eGFR)。随机效应模型用于汇集标准平均差（SMD）和比值比（OR），CI为95％。在P小于0.05时认为有统计学意义。
■纳入三个RCT，涉及563例患者。山莨菪碱与CIN发生率降低相关[OR：0.44;95%CI：0.28,0.69;P=0.0003],在48[SMD：-6.78;95％CI：-10.54，-3.02;P=0.0004]和72h[SMD：-6.74;95％CI：-13.33，-0.15;P=0.03]时，血清肌酐水平降低，24时eGFR较高[SMD：5.77；95%CI：0.39，11.14；P=0.03]，和48h[SMD：4.70；95%CI：2.03,7.38；P=0.0006]。两组24h时的血清肌酐水平和72h时的eGFR值具有可比性。
■山莨菪碱在改善AMI患者PCI后CIN的发展方面具有临床疗效。大,多中心随机对照试验是必要的,以评估这些结果的稳健性.
